注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Plus Therapeutics Inc是一家临床阶段的制药公司。该公司专注于开发癌症患者诊疗方案。该公司提供纳米技术平台来重新制定和改进主管化学治疗方法,使患者和医疗保健提供者受益。该公司专注于开发非专利肿瘤药物,以解决未满足的医疗和市场需求。该公司的候选铅产品DocePlus是一种白蛋白稳定的聚乙二醇化多西紫杉醇脂质体制剂,开发用于治疗小细胞肺癌(SCLC)。该公司还开发了DoxoPLUS,一种非专利的聚乙二醇化脂质体制剂,开发用于治疗乳腺癌、卵巢癌,多发性骨髓瘤和Kaposi的肉瘤。该公司还专注于开发Rhenium -186 NanoLiposome(186RNL),用于治疗复发性胶质母细胞瘤,以及罕见和致命疾病。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Richard J. Hawkins | 72 | 2007 | Independent Chairman of the Board |
Robert P. Lenk | 73 | 2020 | Independent Director |
Vladimir P. Torchilin | 74 | 2020 | Member of Scientific Advisory Board |
John C. McKew | 57 | 2020 | Member of Scientific Advisory Board |
Andrew J. Brenner | - | 2020 | Member of Scientific Advisory Board |
Marc H. Hedrick | 58 | 2002 | President, CEO & Director |
An van Es-Johansson | 61 | 2020 | Independent Director |
Howard Clowes | 67 | 2020 | Independent Director |
Michael Vogelbaum | - | 2020 | Member of Clinical Advisory Board |
Gregory B. Petersen | 58 | 2020 | Independent Director |
Nicholas Butowski | - | 2020 | Member of Clinical Advisory Board |
Manish Aghi | - | 2020 | Member of Clinical Advisory Board |
Alireza Mohammadi | - | 2020 | Member of Clinical Advisory Board |
Russell Lonser | - | 2020 | Member of Clinical Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核